Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2026 | Developing an app to allow patients and caregivers to document chronic GvHD

Daniel Wolff, MD, PhD, University Hospital of Regensburg, Regensburg, Germany, discusses the development of an app for patients and caregivers to document chronic graft-versus-host disease (GvHD), highlighting the potential benefits of remote monitoring for earlier symptom detection and improved treatment outcomes. Dr Wolff notes that patient-reported symptom documentation can be as reliable as physician documentation, reducing inter-rater variability and enabling more accurate longitudinal tracking of the disease. This interview took place at the 52nd Annual Meeting of the EBMT in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

First of all, patients develop chronic GVHD disease through a time where they don’t show up that frequently at the BMT aftercare unit and so they may already come with severe symptoms just because of the time interval and to capture those symptoms earlier, kind of in remote monitoring would be of benefit not to wait until real bad damage occurred to start with treatment...

First of all, patients develop chronic GVHD disease through a time where they don’t show up that frequently at the BMT aftercare unit and so they may already come with severe symptoms just because of the time interval and to capture those symptoms earlier, kind of in remote monitoring would be of benefit not to wait until real bad damage occurred to start with treatment. That was motivation number one. The second motivation was that patients know themselves very well if they document the symptoms and that may be as reliable as physician documentation. The physician is changing and there is an inter-rater variability which may affect longitudinal documentation and eliminating this by teaching patients how to assess where severity may also be of benefit. And actually, that’s what we exactly show, that there is not a great difference between experienced physician GVHD disease rating versus patient rating. So for that part, we were successful. And that just indicates that we may just integrate patients more in assessing the course of disease. So, we pilot that and now is the question how we go from here.

 

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...